UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 13, 2019
CATALYST BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-51173 | 56-2020050 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
611 Gateway Boulevard, Suite 710 South San Francisco, California | 94080 | |||
| (Address of principal executive offices) | (Zip Code) | |||
(650)871-0761
Registrant’s telephone number, including area code
Check the appropriate box below if theForm 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock | CBIO | Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) orRule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the annual meeting of stockholders of Catalyst Biosciences, Inc. (the “Company”) held on June 13, 2019 (the “Annual Meeting”), there were 9,044,948 shares represented to vote either in person or by proxy, or 75.5% of the outstanding shares, which represented a quorum. The final results of voting for each matter submitted to a vote of stockholders at the Annual Meeting were as follows:
Proposal 1: Election of Directors.
Augustine Lawlor and Eddie Williams were elected as Class I directors for a term of three years. The voting for each director was as follows:
| For | Withheld | Broker Non-Vote | ||||||||||
Augustine Lawlor | 5,528,077 | 597,130 | 2,919,741 | |||||||||
Eddie Williams | 6,098,134 | 27,073 | 2,919,741 | |||||||||
Proposal 2: Say on Pay – Anon-binding advisory vote to approve the compensation of the Company’s Named Executive Officers.
The compensation of the Company’s Named Executive Officers was approved on anon-binding, advisory basis based upon the following votes:
| For | Against | Abstain | Broker Non-Vote | |||
| 4,656,959 | 769,185 | 699,063 | 2,919,741 |
Proposal 3: Ratification of Appointment of Independent Registered Public Accounting Firm for the Company for the Current Fiscal Year.
The appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for fiscal year 2019 was ratified based upon the following votes:
| For | Against | Abstain | Broker Non-Vote | |||
| 8,977,727 | 38,321 | 28,900 | 0 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CATALYST BIOSCIENCES, INC. | ||||||
| Date: June 17, 2019 | ||||||
/s/ Nassim Usman, Ph.D. | ||||||
| Nassim Usman, Ph.D. | ||||||
| Chief Executive Officer and President |